These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

859 related articles for article (PubMed ID: 19780248)

  • 21. [Novel molecular approaches in the therapy of advanced colorectal carcinoma].
    Vanhoefer U
    Onkologie; 2003 Dec; 26 Suppl 7():70-4. PubMed ID: 14716146
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Impact of mutational status of KRAS in the care of patients with colorectal cancer metastasis].
    Assenat E; Ychou M
    Bull Cancer; 2009 Dec; 96 Suppl():S41-6. PubMed ID: 20034869
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel approaches to treatment of advanced colorectal cancer with anti-EGFR monoclonal antibodies.
    Zhang W; Gordon M; Lenz HJ
    Ann Med; 2006; 38(8):545-51. PubMed ID: 17438669
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer.
    Köhne CH; Lenz HJ
    Oncologist; 2009 May; 14(5):478-88. PubMed ID: 19411318
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monoclonal antibodies targeting epidermal growth factor receptor and vascular endothelial growth factor with a focus on head and neck tumors.
    Caponigro F; Formato R; Caraglia M; Normanno N; Iaffaioli RV
    Curr Opin Oncol; 2005 May; 17(3):212-7. PubMed ID: 15818163
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biomarker-driven EGFR therapy improves outcomes in patients with metastatic colorectal cancer.
    Hendifar A; Tan CR; Annamalai A; Tuli R
    Expert Rev Anticancer Ther; 2014 Sep; 14(9):1051-61. PubMed ID: 24898788
    [TBL] [Abstract][Full Text] [Related]  

  • 27. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.
    Sobrero AF; Maurel J; Fehrenbacher L; Scheithauer W; Abubakr YA; Lutz MP; Vega-Villegas ME; Eng C; Steinhauer EU; Prausova J; Lenz HJ; Borg C; Middleton G; Kröning H; Luppi G; Kisker O; Zubel A; Langer C; Kopit J; Burris HA
    J Clin Oncol; 2008 May; 26(14):2311-9. PubMed ID: 18390971
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer.
    Moosmann N; Heinemann V
    Clin Colorectal Cancer; 2008 Mar; 7(2):110-7. PubMed ID: 18501070
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer.
    Patel DK
    Pharmacotherapy; 2008 Nov; 28(11 Pt 2):31S-41S. PubMed ID: 18980550
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.
    Chung KY; Shia J; Kemeny NE; Shah M; Schwartz GK; Tse A; Hamilton A; Pan D; Schrag D; Schwartz L; Klimstra DS; Fridman D; Kelsen DP; Saltz LB
    J Clin Oncol; 2005 Mar; 23(9):1803-10. PubMed ID: 15677699
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines.
    Lenz HJ; Van Cutsem E; Khambata-Ford S; Mayer RJ; Gold P; Stella P; Mirtsching B; Cohn AL; Pippas AW; Azarnia N; Tsuchihashi Z; Mauro DJ; Rowinsky EK
    J Clin Oncol; 2006 Oct; 24(30):4914-21. PubMed ID: 17050875
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer.
    Hebbar M; Wacrenier A; Desauw C; Romano O; Cattan S; Triboulet JP; Pruvot FR
    Anticancer Drugs; 2006 Aug; 17(7):855-7. PubMed ID: 16926635
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Update on clinical data with regimens inhibiting angiogenesis and epidermal growth factor receptor for patients with newly diagnosed metastatic colorectal cancer.
    Cohen DJ; Hochster HS
    Clin Colorectal Cancer; 2007 Dec; 7 Suppl 1():S21-7. PubMed ID: 18361803
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Application of monoclonal antibody in combination with irinotecan in the treatment of colorectal cancer].
    Li J
    Zhonghua Zhong Liu Za Zhi; 2006 Oct; 28(10):796-7. PubMed ID: 17366800
    [No Abstract]   [Full Text] [Related]  

  • 35. Molecular mechanisms and targeting of colorectal cancer.
    Vanhoefer U
    Semin Oncol; 2005 Dec; 32(6 Suppl 8):7-10. PubMed ID: 16360005
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-EGFR monoclonal antibodies in metastatic colorectal cancer: time for an individualized approach?
    Fakih M
    Expert Rev Anticancer Ther; 2008 Sep; 8(9):1471-80. PubMed ID: 18759698
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cetuximab: new drug. Metastatic colorectal cancer: an inappropriate evaluation.
    Prescrire Int; 2005 Dec; 14(80):215-7. PubMed ID: 16400742
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Angiogenesis inhibition in the treatment of colorectal cancer Part 3 of a 3-part series: targeting VEGF--current and future research directions.
    Goldberg RM; Hurwitz HI; Fuchs CS
    Clin Adv Hematol Oncol; 2005 Dec; 3(12):1-10; quiz 11. PubMed ID: 16555433
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dual Inhibition of EGFR and VEGF in Heavily Pretreated Patients with Metastatic Colorectal Cancer.
    Larsen FO; Markussen A; Nielsen D; Colville-Ebeling B; Riis LB; Jensen BV
    Oncology; 2017; 93(3):191-196. PubMed ID: 28531891
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biological agents in non-small cell lung cancer: a review of recent advances and clinical results with a focus on epidermal growth factor receptor and vascular endothelial growth factor.
    Kelly K; Huang C
    J Thorac Oncol; 2008 Jun; 3(6):664-73. PubMed ID: 18520811
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.